Search Within

Monica Nancy Fornier

Formats
  1. Journal Article (92)
  2. Meeting Abstract (63)
  3. Review (2)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (158)
  2. Department of Medicine (158)
  3. Solid Tumor Oncology Division (158)
  4. Survivorship Research (158)
  5. Epidemiology and Biostatistics (64)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (58)

More Groups

People
  1. Clifford Hudis (72)
  2. Larry Norton (53)
  3. Chau Dang (38)
  4. Gabriella D'Andrea-Carlino (38)
  5. Andrew Seidman (37)
  6. Diana Lake (36)

More People

Years
  1. 2024 (3)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (3)
  5. 2020 (6)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. Breast Cancer Research and Treatment (15)
  3. Annals of Oncology (11)
  4. Cancer Research (11)
  5. Clinical Breast Cancer (8)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Springer (21)
  3. American Association for Cancer Research (19)
  4. Elsevier Inc. (17)
  5. Oxford University Press (13)
  6. Wiley Blackwell (10)

More Publishers

Results (158)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2-positive breast cancer: Beyond trastuzumab
    Journal Article

    Murphy, C. G.; Fornier, M.
    Oncology (Norwalk) (2010)

    Fulltext@MSK | Save
  • Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity
    Journal Article

    Lin, H.; de Stanchina, E.; Zhou, X. K.; Hong, F.; Seidman, A.; Fornier, M.; Xiao, W. L.; Kennelly, E. J.; Wesa, K.; Cassileth, B. R.; more...
    Cancer Immunology, Immunotherapy (2010)

    Fulltext@MSK | Save
  • Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: Two clinical trials
    Journal Article

    Fornier, M.
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Denosumab: Second chapter in controlling bone metastases or a new book?
    Journal Article

    Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era
    Journal Article

    Damast, S.; Ho, A. Y.; Montgomery, L.; Fornier, M. N.; Ishill, N.; Elkin, E.; Beal, K.; McCormick, B.
    International Journal of Radiation Oncology, Biology, Physics (2010)

    Fulltext@MSK | Save
  • Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines
    Journal Article

    Comen, E.; Fornier, M.
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save